The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Nanotherapeutics in the EU: an overview on current state and future directions
Open accessAbstract
The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug's therapeutic index, and reduce a drug's immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most successful and commercialized categories within the field of nanomedicine. We discuss the regulatory pathway and initiatives endeavoring to ensure the safe and timely clinical translation of emerging nanotherapeutics and realization of health care benefits. Emerging trends are expected to confirm that this nano-concept can exert a macro-impact on patient benefits, treatment options, and the EU economy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Microemulsion-based media as novel drug delivery systems
Lawrence, M. J., & Rees, G. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00103-4 · Cited by 2,040
Safe handling of nanotechnology
Maynard, A. D., Aitken, R. J., Butz, T., Colvin, V., Donaldson, K., Oberdörster, G., Philbert, M. A., Ryan, J., Seaton, A., Stone, V., et al. (2006) · Nature · doi:10.1038/444267a · Cited by 1,496
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
KECK, C., & MULLER, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.009 · Cited by 1,061
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“Although nanoparticles have been studied for approximately 40 years, the anticancer drug Abraxane (Celgene Europe Ltd, Uxbridge, UK) (paclitaxel stabilized by albumin) is the only polymeric nanoparticle-based product on the market (Figure 2).(55) The albumin–paclitaxel formulation consists of 130 nm diameter nanoparti…”
Nanonization strategies for poorly water-soluble drugs
Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.009 · Cited by 642
Physicochemical Principles of Pharmacy
Florence, A. T., & Attwood, D. (1981) · doi:10.1007/978-1-349-19480-3 · Cited by 587
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Nanoparticles in modern medicine: state of the art and future challenges.
(2007) · PubMed Central · Cited by 484
Stable drug encapsulation in micelles and microemulsions
NARANG, A., DELMARRE, D., & GAO, D. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.08.057 · Cited by 419
Medical Applications of Liposomes
(1998) · Elsevier eBooks · doi:10.1016/b978-0-444-82917-7.x5000-5 · Cited by 416
Nanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z. (., & Shin, D. M. (2009) · Nanoscience and Technology · doi:10.1142/9789814287005_0025 · Cited by 321
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., & Glück, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292
Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery
Brough, C., & Williams, R. O. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.061 · Cited by 288
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
Safety assessment of nanomaterials: Implications for nanomedicine
Nyström, A. M., & Fadeel, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.027 · Cited by 264
Jahn, M. R., Andreasen, H. B., Fütterer, S., Nawroth, T., Schünemann, V., Kolb, U., Hofmeister, W., Muñoz, M., Bock, K., Meldal, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.03.016 · Cited by 256
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates
Zhang, X.-X., Eden, H. S., & Chen, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.023 · Cited by 243
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
Bovier, P. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1141 · Cited by 233
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Engineered nanomaterial uptake and tissue distribution: from cell to organism
Huwyler, J., Kettiger, H., Schipanski, A., & Wick, P. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s49770 · Cited by 210
Maynard, A. D. (2011) · Nature · doi:10.1038/475031a · Cited by 210
Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury
Zager, R. A., Johnson, A. C. M., Hanson, S. Y., & Wasse, H. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33917 · Cited by 209
Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations
Desai, P. P., Date, A. A., & Patravale, V. B. (2012) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2011.12.001 · Cited by 199
Clinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 175
Angst, M. S., & Drover, D. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00002 · Cited by 173
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir
Pavelić, Ž., Škalko‐Basnet, N., Filipović‐Grčić, J., Martinac, A., & Jalšenjak, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.032 · Cited by 149
Yokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 133
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 128
Effect of Crystal Size on the In Vitro Dissolution and Oral Absorption of Nitrendipine in Rats
Xia, D., Cui, F., Piao, H., Cun, D., Piao, H., Jiang, Y., Ouyang, M., & Quan, P. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0200-0 · Cited by 120
Nanomedicine: promises and challenges for the future of public health
Brenner, S. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13816 · Cited by 114
How do polymeric micelles cross epithelial barriers?
Pepić, I., Lovrić, J., & Filipović-Grčić, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.012 · Cited by 102
Golan, O. G., Hansen, P., Kaplan, G., & Tal, O. (2010) · Health Policy · doi:10.1016/j.healthpol.2010.10.012 · Cited by 102
Drug targeting systems for inflammatory disease: One for all, all for one
Crielaard, B. J., Lammers, T., Schiffelers, R. M., & Storm, G. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.014 · Cited by 101
Lecithin/chitosan nanoparticles for transdermal delivery of melatonin
Hafner, A., Lovrić, J., Pepić, I., & Filipović‐Grčić, J. (2011) · Journal of Microencapsulation · doi:10.3109/02652048.2011.622053 · Cited by 101
Self-citationA Nonionic Surfactant/Chitosan Micelle System in an Innovative Eye Drop Formulation
Pepić, I., Hafner, A., Lovrić, J., Pirkić, B., & Filipović‐Grčić, J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22137 · Cited by 94
Self-citationA Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 90
Developing Health Technology Assessment to address health care system needs
Garrido, M. V., Gerhardus, A., Røttingen, J., & Busse, R. (2009) · Health Policy · doi:10.1016/j.healthpol.2009.10.002 · Cited by 87
Usonis, V., Bakasénas, V., Valentelis, R., Katiliene, G., Vidzeniene, D., & Herzog, C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00509-7 · Cited by 72
Borchard, G., Flühmann, B., & Mühlebach, S. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.08.009 · Cited by 66
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 59
Emerging health technologies: Informing and supporting health policy early
Wild, C., & Langer, T. G. (2008) · Health Policy · doi:10.1016/j.healthpol.2008.01.002 · Cited by 57
Nanomedicine: Drivers for development and possible impacts
Wagner, V., Hüsing, B., & Gaisser, S. (2008) · Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) · Cited by 46
Drug Targeting to Tumors: Principles, Pitfalls and (Pre-) Clinical Progress
Lammers, T., Kiessling, F. M., Hennink, W. E., et al. (2020) · doi:10.1201/9780429399039-6 · Cited by 43
Toward the practical implementation of eye-related bioavailability prediction models
Pepić, I., Lovrić, J., Cetina‐Čižmek, B., Reichl, S., & Filipović‐Grčić, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.002 · Cited by 40
Huber, F.-X., McArthur, N., Heimann, L., Dingeldein, E., Cavey, H., Palazzi, X., Clermont, G., & Boutrand, J.-P. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-164 · Cited by 38
The politics of health technology assessment in Poland
Ozierański, P., McKee, M., & KING, L. P. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.10.001 · Cited by 34
Drug delivery research in the European Union's Seventh Framework Programme for Research
Frima, H., Gabellieri, C., & Nilsson, M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.044 · Cited by 21
A new prize system for drug innovation
Gandjour, A., & Chernyak, N. (2011) · Health Policy · doi:10.1016/j.healthpol.2011.06.001 · Cited by 17
On the edge of new technologies (advanced therapies, nanomedicines)
Vamvakas, S., Martinalbo, J., Pita, R., & Isaac, M. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.04.001 · Cited by 13
Potential beneficial role of sevelamer hydrochloride in diabetic retinopathy
Drača, N., Lazić, R., Šimić, P., Dumić-Čule, I., Luetić, A. T., & Gabrić, N. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2012.12.035 · Cited by 6
Cited by
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Nanoprecipitation process: From encapsulation to drug delivery
Martínez Rivas, C. J., Tarhini, M., Badri, W., Miladi, K., Greige-Gerges, H., Nazari, Q. A., Galindo Rodríguez, S. A., Román, R. Á., Fessi, H., & Elaissari, A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.08.064 · Cited by 733
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Metadata
- Authors
- Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2014-02
- Volume
- 9
- Pages
- 1005
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1971938726
- Cited by
- 294
- References
- 71
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.